At a glance
ClinicalIndex Comparison RecordN/ACompleted· 452 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
In Brief
An observational study for Ankylosing Spondylitis. Completed, enrolled 452 participants.
Detailed Summary
The purpose of this study was to assess the proportion of AS patients achieving treatment response to adalimumab therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedDec 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedDec 21, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.5 years ago